Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 May;93(5):1696-701.
doi: 10.1210/jc.2007-2249. Epub 2008 Feb 19.
Affiliations
- PMID: 18285411
- DOI: 10.1210/jc.2007-2249
Randomized Controlled Trial
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial
Dorte Glintborg et al. J Clin Endocrinol Metab. 2008 May.
Abstract
Objective: Our objective was to investigate the effect of pioglitazone on bone mineral density (BMD) and bone turnover markers in polycystic ovary syndrome (PCOS).
Design and setting: We conducted a randomized, placebo-controlled study at an outpatient clinic at a university hospital.
Patients: Thirty premenopausal patients with PCOS and 14 age- and weight-matched healthy females participated.
Interventions: Pioglitazone (30 mg/d) or placebo was given for 16 wk.
Main outcome measures: Measurements of BMD [hip (neck and total) and lumbar spine (L2-L4)], bone metabolic parameters [alkaline phosphatase (ALP), 25-hydroxyvitamin D, C-telopeptide of type I collagen (ICTP), osteocalcin, and PTH], endocrine profiles (testosterone, estradiol, and insulin), and body composition (waist to hip ratio, body mass index, and whole-body dual-energy x-ray absorptiometry scans) were performed.
Results: Patients with PCOS had significantly higher levels of ICTP, fasting insulin, and testosterone than controls, whereas no differences were measured in ALP, PTH, body composition, or BMD. Pioglitazone treatment was followed by reduced BMD [geometric means (-2 to +2 sd)]: lumbar spine 1.140 (0.964-1.348) vs. 1.127 (0.948-1.341) g/cm(2) (average decline 1.1%) and femoral neck 0.966 (0.767-1.217) vs. 0.952 (0.760-1.192) g/cm(2) (average decline 1.4%), both P < 0.05. Both ALP and PTH decreased significantly during pioglitazone treatment, whereas no significant changes were measured in 25-hydroxyvitamin D, ICTP, osteocalcin, sex hormones, and body composition.
Conclusion: Pioglitazone treatment was followed by decreased lumbar and hip BMD and decreased measures of bone turnover in a premenopausal study population relatively protected from bone mineral loss.
Similar articles
- Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
Glintborg D, Støving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, Flyvbjerg A, Andersen M. Glintborg D, et al. J Clin Endocrinol Metab. 2005 Oct;90(10):5605-12. doi: 10.1210/jc.2005-0615. Epub 2005 Aug 2. J Clin Endocrinol Metab. 2005. PMID: 16076946 Clinical Trial. - Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Bone HG, et al. J Clin Endocrinol Metab. 2013 Dec;98(12):4691-701. doi: 10.1210/jc.2012-4096. Epub 2013 Sep 20. J Clin Endocrinol Metab. 2013. PMID: 24057294 Clinical Trial. - Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.
Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR. Aroda VR, et al. J Clin Endocrinol Metab. 2009 Feb;94(2):469-76. doi: 10.1210/jc.2008-1133. Epub 2008 Nov 4. J Clin Endocrinol Metab. 2009. PMID: 18984667 Free PMC article. Clinical Trial. - Thiazolinedione treatment in PCOS--an update.
Glintborg D, Andersen M. Glintborg D, et al. Gynecol Endocrinol. 2010 Nov;26(11):791-803. doi: 10.3109/09513590.2010.491572. Gynecol Endocrinol. 2010. PMID: 20528570 Review. - The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis.
Billington EO, Grey A, Bolland MJ. Billington EO, et al. Diabetologia. 2015 Oct;58(10):2238-46. doi: 10.1007/s00125-015-3660-2. Epub 2015 Jun 25. Diabetologia. 2015. PMID: 26109213 Review.
Cited by
- Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes.
Wang Y, Zhou Y, Zhou X, Su X, Xu X, Li H, Ma J. Wang Y, et al. Diabetes Metab Syndr Obes. 2023 Dec 27;16:4205-4214. doi: 10.2147/DMSO.S439479. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 38162801 Free PMC article. - Relationship between nonalcoholic fatty liver disease and hyperandrogenemia in adolescents with polycystic ovary syndrome.
Kara O, Arsoy HA, Keskin M. Kara O, et al. Clin Exp Pediatr. 2023 Sep;66(9):395-402. doi: 10.3345/cep.2023.00353. Epub 2023 Jun 14. Clin Exp Pediatr. 2023. PMID: 37321582 Free PMC article. - Effects of distinct Polycystic Ovary Syndrome phenotypes on bone health.
Mills EG, Abbara A, Dhillo WS, Comninos AN. Mills EG, et al. Front Endocrinol (Lausanne). 2023 May 12;14:1163771. doi: 10.3389/fendo.2023.1163771. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37251667 Free PMC article. Review. - Vitamin D, Bone Metabolism, and Fracture Risk in Polycystic Ovary Syndrome.
Di Bari F, Catalano A, Bellone F, Martino G, Benvenga S. Di Bari F, et al. Metabolites. 2021 Feb 18;11(2):116. doi: 10.3390/metabo11020116. Metabolites. 2021. PMID: 33670644 Free PMC article. Review. - Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome: A Multicenter Case-Control Study.
Kazemi M, Jarrett BY, Parry SA, Thalacker-Mercer AE, Hoeger KM, Spandorfer SD, Lujan ME. Kazemi M, et al. J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3400-14. doi: 10.1210/clinem/dgaa426. J Clin Endocrinol Metab. 2020. PMID: 32614948 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical